Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Karyopharm Therapeutics (KPTI) PT Lowered to $20 at Wedbush
August 4, 2020 1:44 PM EDTWedbush analyst David Nierengarten lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $20.00 (from $26.00) while maintaining a Neutral rating.
... MoreKaryopharm Therapeutics (KPTI) Misses Q2 EPS by 5c, Revenues Beat
August 4, 2020 7:22 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.63), $0.05 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $33.51 million versus the consensus estimate of $27.42 million.
"Despite the ongoing global COVID-19 pandemic, Karyopharm was able to achieve record quarterly XPOVIO sales as well as execute on several important initiatives, including receiving approval of XPOVIO for its second cancer indication from the U.S. Food and Drug Administration (FDA) to treat patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). XPOVIO is now the only single-agent oral therapy approved in this... More
